Immunomodulatory effect of Quercetin on dysregulated Th1/Th2 cytokine balance in mice with both type 1 diabetes and allergic asthma

Nutakki Ravikumar*, Chilaka Naga Kavitha
Department of Pharmacology, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, India.

ARTICLE INFO
Received on: 14/12/2019
Accepted on: 16/01/2020
Available online: 05/03/2020

Key words:
Quercetin, Th1/Th2 balance, ovalbumin, comorbid diabetic asthma, allergic inflammation.

ABSTRACT
T-helper subtype imbalance is intricate in type 1 diabetes (T1D) and asthma initiation. The role of quercetin in immune dysregulation in comorbid conditions of T1D and asthma is not available. In this study, it was thought worthy to evaluate the role of quercetin on modulating Th1/Th2 cytokine dysregulation in comorbid diabetic asthma. Male Balb/c mice were injected intravenously with alloxan (80 mg/kg) to persuade T1D. Succeeding diabetes introduction, two intraperitoneal sensitizing doses of ovalbumin emulsion (50 µg ovalbumin blended with 2.5 mg alum/sensitization) were given on days 3 and 8. Mice were given intranasal challenges of ovalbumin (100 µg ovalbumin/25 µl of sterile saline) on days 13–15. Oral quercetin treatment (10–30 mg/kg) was given daily on days 3–15. Nasal hyperresponsiveness (NHR) was recorded immediately after Ova challenge on day 16. Bronchoalveolar lavage fluid (BALF), blood, and lungs were collected 1-hour post NHR for further analysis. Quercetin treatment significantly decreased eosinophils, interleukin-4 while increasing interferon-gamma in blood, and BALF and reduced the allergic airway inflammation by inhibiting inflammatory cell infiltration and mucous cell metaplasia. Furthermore, quercetin with a dose of 30 mg/kg demonstrated a significant glucose reduction. Thus, quercetin exerted dose-dependent anti-asthma activity by modulating Th1/Th2 balance with glucose-lowering potential in comorbid mice.

INTRODUCTION
Autoimmune type 1 diabetes and asthma result from a dysregulated balance of T-helper 1/T-helper 2 (Th1/Th2) immune responses. A simultaneous presentation of these two diseases in patients may disclose the involvement of few common pathophysiological mechanisms that mediate the immune dysregulation in these two conditions (Rottem and Shoenfeld, 2003). Autoimmune Th1 and Th2 responses are implicated in the development of type 1 diabetes (T1D) and allergic asthma, respectively (Metsala et al., 2018). However, few evidence indicate the role of Th1 in severe asthma exacerbations and Th2 in T1D pathophysiology (Rachmiel et al., 2006). The association between the incidence of T1D and asthma is still a point of discussion, and the loss of immune system balance at early age due to the interaction between inherent susceptibility and environmental triggers may govern the development of these clinical diseases (Rachmiel et al., 2006; Stene and Nafstad, 2001; Zoka et al., 2013). Cardwell et al. (2003) reported a decrease of asthma occurrence in T1D patients from a meta-analysis of clinical literature, whereas Hsiao et al. (2015) showed a higher rate of asthma occurrence in T1D patients from a nationwide population-based study in Taiwan.

Cytokines play an integral role in the exacerbations of asthma and pathogenesis of T1D and mediate an inflammation along with several other inflammatory cells (Mahajan and Mehta, 2006; Rabinovitch and Suarez-Pinzon, 2007). Increased interferon-gamma (IFN-γ), secreted by autoreactive Th1 cells, and oversecretion of interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) by autoreactive Th2 cells have been observed in T1D and asthma, respectively (Guo et al., 2018; Levine and Wenzel, 2010; Park et al., 2013; Mazzarella et al., 2000; Xiangyang et al., 2006). In general, the IFN-γ/IL-4 ratio...
is used to define the predominant T-helper (Th) phenotype (Salvi et al., 2001). An intermediary cytokine secretory pattern that combines the features of both T1D and asthma with a unique IFN-γ/IL-4 ratio is noticed in the patients with both these diseases (Rachmiel et al., 2006).

Flavonoids are polyphenolic plant compounds that have been extensively studied for their immunomodulatory effects in experimental models of asthma and diabetes. They have been shown to inhibit the synthesis of IL-4 and its related signal transduction mechanisms in an animal model of asthma and allergy (Jurokova et al., 2015; Tanaka and Takahashi, 2013). Furthermore, these polyphenols have shown to play protective roles in glucose homeostasis by modulating the immune system (Vinayagam and Xu, 2015). Quercetin is a flavonol consisting of two aromatic rings that are linked by heterocyclic ring having oxygen moiety in it. Quercetin has shown to inhibit airway hypersensitivity, inflammation and mucous secretion with associated reductions in IL-4, and Th2 immune responses in ovalbumin-sensitized and challenged mice (Fortunato et al., 2012; Park et al., 2009). Furthermore, quercetin has shown to attenuate alloxan-induced hyperglycemia in mice (Zhang et al., 2016). Moreover, quercetin has shown immune modulation in several other disease conditions such as influenza A virus infection (Mehrbod et al., 2018), dengue virus infection (Jasso-Miranda et al., 2019), Japanese encephalitis virus infection (Johari et al., 2012), experimental cirrhosis (Casas-Grajales et al., 2017), rheumatoid arthritis (Al-Rekabi et al., 2015; Javadi et al., 2017), and multiple sclerosis (Sternberg et al., 2008). However, its immunomodulatory role in comorbid conditions of T1D and asthma has never been tested despite its potential to alleviate both diabetes and asthma. The previous study results indicated the presence of dysregulated and a unique Th1/Th2 cytokine balance in mice challenged with T1D and allergic asthma (Ravikumar and Kavitha, 2019). Moreover, quercetin has shown immune modulation.

In the present study, it was believed creditable to determine the immunomodulatory effect of quercetin on dysregulated Th1/Th2 immune balance in mice with both T1D and allergic asthma.

MATERIALS AND METHODS

Animals

Adult male Balb/c mice of Taconic background and having the age between 6 and 8 weeks were obtained from Vivo Bio Tech Ltd., India. Mice were acclimatized for 5 days before the experimentation and were housed individually for the entire study period. The mice were provided with free access to standard rodent diet and water and were maintained on a 12-hour dark/light cycle in controlled housing conditions of temperature (19°C–25°C), relative humidity (30%–70%), and air changes (15–20 per hour). The animal procedures were conducted as per the approved protocol (VB/IAEC/07/2019/360/Mouse/Balb/c) by the Institutional Animal Ethics Committee (IAEC) of Vivo Bio Tech Ltd.

Experimental design and treatment protocol

After acclimatization period, based on their body weight, the mice were randomized into six groups (n = 6 per group): (1) non-diabetic asthma + vehicle, (2) non-diabetic asthma + quercetin 10 mg/kg, (3) non-diabetic asthma + quercetin 30 mg/kg, (4) diabetic asthma + vehicle, (5) diabetic asthma + quercetin 10 mg/kg, and (6) diabetic asthma + quercetin 30 mg/kg. The non-diabetic asthma group animals were induced with asthma alone, whereas diabetic asthma animals were induced with both T1D and asthma as per the procedures mentioned below. Quercetin (sourced from Bulk Supplements, Henderson, NV) was dissolved in 1% dimethyl sulfoxide (DMSO) and dosed orally on every day for 13 days from day 3 to 15. Vehicle animals received 1% DMSO/kg body weight orally. Daily body weights and clinical signs were noted until the end of the study.

Alloxan-induced diabetes

The mice in the diabetic groups were injected intravenously (i.v.) with 80 mg/kg of alloxan monohydrate (Sigma-Aldrich, India) dissolved freshly in sterile water after a brief fasting period of 3 hours on day 0, as described previously with slight modification (Pettersson et al., 2011). The induction of T1D was verified after 72 hours of alloxan injection by drawing blood through tail prick and checking blood glucose levels using Accu-Chek Aviva glucometer (Roche Diagnostics). The blood glucose level >250 mg/dl was considered as T1D for the study.

Ovalbumin-induced asthma

The mice in both the non-diabetic and diabetic groups were sensitized twice on days 3 and 8 with an intraperitoneal (i.p) injection of 50 µg ovalbumin (Ova) emulsified in 2.5 mg of aluminum hydroxide (Al(OH)3 in 0.2 ml of PBS. Following sensitization, on days 13–15, all mice received an intranasal challenge with 100 µg of Ova in 25 µl of sterile saline (4% w/v Ova) 1 hour later to compound treatment as described previously with modifications (Carvalho et al., 2018; Fernandez-Rodriguez et al., 2008).

Nasal hyperresponsiveness (NHR) evaluation

About 24 hours after last compound treatment and following asthma induction, on day 16, once again all the mice were challenged intranasally with 100 µg of Ova in 25 µl of sterile saline (4% w/v Ova). Immediately after the last Ova challenge, the nose rubbing frequency in each mouse was counted as a measure of upper airway hyperresponsiveness as described previously (Zhang et al., 2016).

Blood glucose levels and leukocyte count

Following NHR evaluation, random blood glucose levels were estimated using Accu-Chek Aviva glucometer (Roche

![Figure 1. Alloxan-induced hyperglycemia reduces after quercetin treatment. The random blood glucose was measured using glucometer on day 16 from blood withdrawn through tail prick. Data (n = 6) are represented as mean ± SEM, **p < 0.01 versus vehicle.](image-url)
Diagnosits from blood samples drawn through tail prick. Later, blood was withdrawn through retro-orbital plexus and collected one aliquot in ethylenediaminetetraacetic acid tubes and other aliquot in serum separator tubes. The total leukocyte count of the blood was assessed using a hematology analyzer (Medonic CA620), and differential leukocytes were counted manually after Giemsa staining of blood smear. The percentage of differential leukocyte count (DLC) was multiplied with total leukocyte count to derive the absolute differential leukocyte count. Serum was separated after centrifuging blood at 10,000 rpm for 5 minutes at 4°C and stored at ~80°C for cytokine estimations using the Enzyme-linked immunosorbent assay (ELISA) kit.

**Bronchoalveolar lavage fluid (BALF)**

The mice were euthanized by CO2 asphyxiation immediately after blood collection, and the chest cavity was opened. A tracheal cannula was inserted, 0.8 ml of PBS was infused into the lungs, and BALF was collected. The procedure was repeated twice to collect maximum amount of BALF. Immediately after collection, BALF was centrifuged at 2,500 rpm for 10 minutes at 4°C, and the supernatant was collected and stored at −80°C for cytokine estimations using ELISA kit. A 250 µl of PBS was added to the lavage pellet, and the total leukocytes were counted with Medonic CA620 hematology analyzer. The differential leukocyte counts in BALF were estimated manually after staining of BALF smear with Giemsa, and the absolute DLCs in BALF were derived by multiplying the percentage of DLC with total leukocytes in BALF.

**Necropsy and lung histopathology**

Gross observation of the spleen and internal organs was carried during necropsy, and the spleen weights were noted. The lungs of mice in each group (n = 2) were collected in 10% formalin and embedded in paraffin blocks. The sections (4 µm) were made and stained with hematoxylin and eosin (H and E). The H and E-stained lung sections were observed for inflammatory cell aggregates and mucous cell metaplasia around airways as a measure of airway inflammation by a pathologist who was unaware of the treatment details of each group. The mucous cell metaplasia was graded as follows: 0 = no difference, 1 = scattered mucous cells, 2 = aggregates of mucous cells, 3 = monolayer of mucous cells, and 4 = multilayered mucous cells.

**Th1/Th2 cytokines in serum and BALF**

The level of IFN-γ as Th1 responsive cytokine and IL-4 and IL-10 as Th2 responsive cytokines was assessed by ELISA method in both serum and BALF, following kits’ manual (Invitrogen Mouse Th1/Th2 ELISA kit, cat # 88-7711-44). The assay was conducted in 96-well format, and the ODs were obtained by reading the plate using a microplate reader (Multiskan GO, Thermo Scientific). The unknown concentrations were derived from extrapolation of the standard curve constructed using mouse IFN-γ (assortment: 15–2,000 pg/ml), mouse IL-4 (assortment: 4–500 pg/ml), and mouse IL-10 (assortment: 30–4,000 pg/ml).

**Statistical analysis**

All statistical analyses and graphs were created using GraphPad Prism 8.1 software. The data were analyzed using a one-way analysis of variance, followed by Tukey’s multiple comparison test or unpaired Student’s t-test wherever applicable, and the p < 0.05 was considered to be significant.

**RESULTS AND DISCUSSION**

**Quercetin reduces alloxan-induced hyperglycemia in diabetic asthma mice**

Balg/c mice presented a significant rise in blood glucose at 72 hours (day 3) after single alloxan injection with a concomitant decrease in body weight, suggesting T1D state in these mice (Table 1). Quercetin treatment showed a dose-dependent decrease in alloxan-induced hyperglycemia with a significant reduction at 30 mg/kg dose compared to the vehicle-treated diabetic asthma mice (Fig. 1). Nearly, 17% and 47% decrease in glucose were observed with 10 and 30 mg/kg doses of quercetin, respectively. The glucose reduction potential of quercetin has been widely tested and stated in quite a few animal models of diabetes (Zhang et al., 2016; Yang and Kang, 2018). Although the previous reports were all in pure diabetic models, the glucose reduction potential of quercetin in the diabetic asthma model could be related to its strong antioxidant- and β-cell-protective actions along with modulation of Th1/Th2 immune balance in these mice. In addition, quercetin at 30 mg/kg dose significantly reduced the percentage body weight loss (19.60% vs. 16.04%) than vehicle-treated mice (Table 2).

**Quercetin inhibits nasal hyperresponsiveness after ovalbumin challenge in both non-diabetic and diabetic asthma mice**

To understand the immunomodulatory role of quercetin, its effect on allergen-induced hyperresponsiveness was tested first. The allergen-induced allergic hyperreactivity of upper airways was assessed by measuring the number of nose rubbings as a measure of nasal hyperresponsiveness immediately after

<table>
<thead>
<tr>
<th>Group</th>
<th>Random blood glucose (mg/dl)</th>
<th>Body weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic asthma + vehicle</td>
<td>382.00 ± 50.70***</td>
<td>22.58 ± 6.05</td>
</tr>
<tr>
<td>Diabetic asthma + quercetin 10 mg/kg</td>
<td>376.83 ± 46.34***</td>
<td>23.71 ± 5.02</td>
</tr>
<tr>
<td>Diabetic asthma + quercetin 30 mg/kg</td>
<td>383.00 ± 40.65***</td>
<td>22.55 ± 3.65</td>
</tr>
</tbody>
</table>

Data (n = 6) are showed as mean ± SEM.

<table>
<thead>
<tr>
<th>Group</th>
<th>% body weight change</th>
<th>Relative spleen weight (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nondiabetic asthma + vehicle</td>
<td>3.04 ± 1.15</td>
<td>0.59 ± 0.04</td>
</tr>
<tr>
<td>Nondiabetic asthma + quercetin 10 mg/kg</td>
<td>3.18 ± 1.76</td>
<td>0.48 ± 0.03</td>
</tr>
<tr>
<td>Nondiabetic asthma + quercetin 30 mg/kg</td>
<td>1.97 ± 1.14</td>
<td>0.47 ± 0.06</td>
</tr>
<tr>
<td>Diabetic asthma + vehicle</td>
<td>16.04 ± 8.12</td>
<td>0.35 ± 0.04</td>
</tr>
<tr>
<td>Diabetic asthma + quercetin 10 mg/kg</td>
<td>13.15 ± 2.91</td>
<td>0.27 ± 0.04</td>
</tr>
<tr>
<td>Diabetic asthma + quercetin 30 mg/kg</td>
<td>9.60 ± 0.96##</td>
<td>0.26 ± 0.05</td>
</tr>
</tbody>
</table>

The percentage body change was calculated using the formula: (Body weight on day 16−body weight on day 3)/body weight on day 3 * 100.

Data (n = 6) are presented as mean ± SEM.

## = p < 0.01 against diabetic asthma vehicle.
challenge with ovalbumin. Untreated non-diabetic and diabetic mice presented almost similar NHR after Ova challenge. The nasal rubbing frequency increased because intranasal Ova challenge was significantly reduced after quercetin treatment at 30 mg/kg dose in both non-diabetic and diabetic asthma mice. Quercetin at 10 mg/kg managed to reduce the NHR at an insignificant level in Ova-sensitized and challenged mice with or without diabetes when compared to vehicle-treated mice (Fig. 2). Similar results were observed by Edo et al. (2018) using 20 mg/kg of quercetin in Ova induced allergic rhinitis model, wherein the reduction in nasal symptoms like nasal rubbing and number of sneezes were reduced. The author proposed that this nasal hyperresponsiveness reduction after quercetin oral treatment was due to increase of thioredoxin production by nasal epithelial cells, which is an antioxidant protein produced endogenously. Partially, we could hypothesize that the reduction of NHR observed after quercetin oral treatment, in this study, would have resulted through this mechanism. Partly, it could have resulted from the inhibition of allergic mediators such as histamine and leukotriene by eosinophils and mast cells (Middleton, 1998). Furthermore, the inhibitory effect of quercetin on the production of nitric oxide in vitro by human epithelial nasal cells (Ebihara et al., 2018) suggests that the antioxidant potential of quercetin may have played a role in reducing the NHR in this study. The observed efficacy of quercetin on the frequency of upper airway hyperactivity was a dose-dependent effect.

Quercetin inhibits Ova-induced allergic airway inflammation in both non-diabetic and diabetic asthma mice

The effect of quercetin on Ova-induced allergic airway inflammation was studied by measuring the inflammatory cell numbers in blood, BALF, and H and E-stained lung sections from samples collected 1 hour after the last Ova challenge in sensitized non-diabetic and diabetic mice. Quercetin treatment (30 mg/kg) of Ova-sensitized and challenged non-diabetic and diabetic mice demonstrated significantly low numbers of Th2 response eosinophils in BALF (Fig. 3a) and blood (Fig. 3b). In general, these outcomes are in agreement with the data published for the protective role of quercetin in ovalbumin-induced asthma (Cai et al., 2017; Rogerio et al., 2007; Sozmen et al., 2016). Furthermore, quercetin has shown to inhibit the eosinophil function and degranulation in in vitro studies after immunological stimuli and shown the ability to constrain the production of inflammatory cytokines by eosinophils (Sakai-Kashiwabara and Asano, 2013).

Furthermore, histopathological observation of H and E-stained lung sections revealed that 30 mg/kg dose of quercetin significantly reduced the mucous cell metaplasia and perivascular inflammatory cell aggregates in both the non-diabetic (Figure 3c and 3d) and diabetic (Figure 3e and 3f) asthma mice after Ova challenge. Quercetin at 10 mg/kg dose also showed improvement in asthma condition by reducing mucous cell and inflammatory cell aggregates around airways in both the non-diabetic and diabetic mice compared to untreated mice. Similarly, the observations were reported by Park et al. (2009) using quercetin in Ova model of asthma, indicating the inhibition of allergen-induced inflammation of airways including the infiltration of eosinophilic Th2 cells into lung airways.

In addition, quercetin treatment showed significantly lower graded mucous cell metaplasia per lung section in sensitized mice after Ova challenge compared to the vehicle treatment. Still, both 10 and 30 mg/kg dosages of quercetin exerted an inhibition of mucous cell metaplasia grading in comorbid diabetic asthma mice, and only 30 mg/kg dose of quercetin showed significance in the case of non-diabetic asthma mice (Fig. 3g).

Quercetin modulates Th1/Th2 cytokine balance in Ova-induced allergic asthma in non-diabetic and diabetic mice

To know the effect of quercetin on Th1/Th2 immune balance, the Th1 and Th2 cytokines were estimated in BALF and serum samples collected post 1 hour of last Ova challenge. The cytokines estimated were IFN-γ as Th1-mediated cytokine secretion and IL-4 and IL-10 as Th2-mediated cytokine secretion. The BALF and serum cytokine levels indicated a significant upregulation of Th2 responsive IL-4 after Ova sensitization and challenge in both the non-diabetic and diabetic mice. The treatment of quercetin at 30 mg/kg dose in these mice significantly lowered the IL-4 levels (Fig. 4b and e) with a corresponding slight increase in IFN-γ (Fig. 4a and d) leading to a significant increase in Th1/Th2 (IFN-γ/IL-4) ratio in both BALF (Fig. 4g) and serum (Fig. 4h). Quercetin at 10 mg/kg dose showed a significant reduction of serum IL-4 in non-diabetic asthma mice compared to the vehicle (Fig. 4c). This result indicated that the reduction of IL-4 triggered an airway inflammation in these mice by quercetin treatment and also suggested the immunomodulatory activity of quercetin on immune dysregulation mediated through Th1/Th2 cytokine imbalance in comorbid conditions of T1D and asthma. The more increase of Th1/Th2 ratio was observed with quercetin treatment on the occasion of comorbid diabetic asthma than in asthma alone (Fig. 4g and h). These results were in harmony with the outcomes by Park et al. (2009), wherein quercetin showed altered polarization of Th1/Th2 balance through GATA3 decrease and T-bet increase in murine Ova asthma model. T-bet and GATA3 are prime controlling transcription factors of T-cell differentiation, especially for Th1 and Th2 lineage responses, respectively (Kanhere et al., 2012).

Interleukin-10 levels were not affected greatly by quercetin treatment although there was a little decrease observed at both the doses in BALF (Fig. 4c) and only at 30 mg/kg dose in serum (Fig. 4f) of these mice when compared to the vehicle treatment.
Figure 3. Decreased infiltration of Th2 responsive inflammatory cells in BALF, blood, and lung airways after quercetin treatment in diabetic mice sensitized and challenged with ovalbumin. Eosinophil cell numbers in a) BALF and b) blood collected 1 hour after the last Ova challenge. c) mucous cell metaplasia in bronchioles (BV) of nondiabetics, d) perivascular (BV) inflammatory cell aggregates in nondiabetics, e) mucous cell metaplasia in diabetics, f) perivascular inflammatory cell aggregates in diabetics, and g) average grading of mucous cell metaplasia per lung section obtained 1 hour after last Ova challenge from sensitized mice. Absolute differential leukocyte counts in BALF and blood were determined by Giemsa staining. Lung tissue inflammation was assessed by H and E staining of lung sections (magnification, ×200). Inflammatory cell aggregation around blood vessel (BV) and mucous cell metaplasia of bronchiole (BR) in the lung sections were shown by arrow. Quercetin at 10 mg/kg and 30 mg/kg is represented as Q10 and Q30, respectively, in lung section figures. Eosinophil data (n = 5–6) and average graded mucous metaplasia (n = 2; 3 lung sections/animal) are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 against non-diabetic vehicle; #p < 0.05 and ##p < 0.01 against diabetic asthma vehicle.
We believe that the present study is the first study that showcased the immunomodulatory effect of quercetin in comorbid diabetic asthma in mice. The inclusion of asthma alone (non-diabetic asthma) groups served as efficacy controls for the anti-asthmatic potential of quercetin. The quercetin treatment of both the diabetic asthma and non-diabetic asthma mice revealed dose-dependent reduction of NHR, eosinophilic Th2 cells, and Th2 responsive IL-4 levels, leading to significant inhibition of the allergic airway inflammation of lungs as evidenced by decreased mucous cell metaplasia and inflammatory cell aggregation around airways in H and E-stained lung sections after Ova challenge. Among the doses tested, quercetin at 30 mg/kg dose showed significant reductions in all parameters of allergic asthma in these mice. The magnitude of efficacy for quercetin at 30 mg/kg dose was similar in both comorbid diabetic asthma and asthma alone conditions, suggesting that its immunomodulatory efficacy against Th1/Th2 cytokine responses was similar in these two conditions.

CONCLUSION
The results in this study indicate that quercetin treatment significantly lowered all the asthma features in both the diabetic and non-diabetic asthma mice, indicating the therapeutic benefits of this compound in the comorbid conditions of type 1 diabetes and asthma. Moreover, quercetin showed immunomodulation in these mice by modifying the altered Th1/Th2 immune balance toward a favorable and balanced immune response, ultimately leading to the alleviation of allergic inflammation in the lungs of these mice. The modulation of Th1/Th2 immune balance in these mice after quercetin treatment was a result of not only fall in Th2 cytokine IL-4 but also due to mild rise in Th1 cytokine IFN-γ. In addition, quercetin treatment at 30 mg/kg improved glycemia and decreased body weight loss in comorbid diabetic asthma mice. Nonetheless, quercetin has offered dose-dependent improvements in both asthma and diabetic illnesses in these mice and modulated the dysregulated immune system that mediated through Th1/Th2 imbalance in these mice.

ACKNOWLEDGMENTS
The authors are grateful to Vivo Bio Tech Ltd. (Hyderabad, India) for providing the animals and laboratory research facilities for this research work. The authors are also thankful to the GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, for providing support to the research work.
AUTHORS’ CONTRIBUTIONS

Ravikumar N has carried out the experimental work and data analysis. Ravikumar N and Kavitha CH. N have designed and drafted the manuscript.

CONFLICT OF INTEREST

The authors declared that they have no conflict of interest.

REFERENCES


Hsiao YT, Cheng WC, Liao WC, Lin CL, Shen TC, Chen WC, Chen CH, Kao CH. Type 1 diabetes and increased risk of subsequent asthma: a nationwide population-based cohort study. Medicine, 2015; 94(36):1–6.


How to cite this article: